A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasisCapsule Summary

Background: DMB-3115 is a biosimilar to Stelara (hereinafter referred to as ustekinumab). Objectives: To evaluate the clinical similarity of DMB-3115 with ustekinumab in patients with moderate-to-severe plaque psoriasis. Methods: In this phase 3, randomized, double-blind, parallel-arm study, adults...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Kamelia Vekovska, MD, Beata Imko-Walczuk, PhD, Martin Tichý, PhD, Zoe Diana Draelos, MD, Petra Cetkovska, PhD, Phoebe Rich, MD, Jolanta Weglowska, MD
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2026-02-01
Schriftenreihe:	JAAD International
Schlagworte:	biologics biosimilar psoriasis randomized clinical trial ustekinumab
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2666328725001130
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!